When was the last time you really reconsidered the power of ultrasound in evaluating prostate disease? For many clinicians, TRUS (transrectal ultrasound) is synonymous with biopsy guidance. It’s mechanical, familiar, and perhaps even taken for granted. But prostate ultrasound is evolving. And if you haven’t revisited its capabilities lately, you may be missing a revolution happening in prostate ultrasound.

Prostate ultrasound is no longer just about finding hypoechoic lesions in the peripheral zone. Thanks to modern advancements such as shear wave elastography, micro-ultrasound, and contrast-enhanced imaging, it’s becoming a serious contender against mpMRI in diagnostic precision. These tools are changing how we assess tissue architecture, identify aggressive disease, and even rethink how biopsies are performed.

Micro-ultrasound, operating at 29 MHz, offers up to 300% higher resolution than conventional TRUS. The real-time visualization it provides is detailed enough to detect subtle architectural changes that MRI might miss. With the PRI-MUS scoring system (Prostate Risk Identification using Micro-Ultrasound), clinicians now have a structured way to risk-stratify lesions without leaving the ultrasound suite.

Meanwhile, shear wave elastography (SWE) is providing functional insight beyond what grayscale can offer. By measuring tissue stiffness, SWE can help us differentiate between benign and malignant areas, especially in the transition zone where conventional imaging often falls short. Have you considered how much additional value elastography could bring to your routine prostate assessments?

The evolving role of contrast-enhanced ultrasound (CEUS) is also noteworthy. With microbubble technology enhancing vascular detail, CEUS is proving useful in targeting suspicious areas. In some cases, it even outperforms MRI in patients with contraindications to gadolinium. Is there a place for CEUS in your practice?

And what about biopsies? While MRI fusion-guided approaches have become popular, micro-ultrasound offers a compelling, MRI-independent alternative. In experienced hands, it may not only match MRI-targeted biopsy accuracy but even outperform it in certain clinical contexts. Could this be the moment to reassess your default workflow?

Across the globe, clinicians are rethinking prostate imaging protocols. In settings where MRI is limited or inaccessible, these advanced ultrasound techniques are not just stand-ins; they are front-line modalities in their own right. We should be teaching residents and sonographers to see prostate ultrasound as more than just a guided-needle pathway.

This isn’t just about technology. It’s about mindset. Are we giving prostate ultrasound the credit it deserves as a dynamic, diagnostic-first tool?

We invite you to reflect on your current practices. Are you leveraging all that modern ultrasound has to offer in prostate disease? Are there barriers—technical, educational, or institutional—that keep your department from integrating these advancements?

Let us know what you think. Share your experiences, your questions, your doubts. The conversation around prostate ultrasound is changing, and we want your thoughts.